October 15, 2026
Action for Pulmonary Fibrosis (APF) welcomes encouraging new trial results that offer the potential for another treatment option for people living with idiopathic pulmonary fibrosis (IPF) in the future.
The ALOFT-IPF trial tested admilparant against a placebo (a tablet containing no active medicine). Participants could take part while continuing their existing antifibrotic treatment with nintedanib or pirfenidone, or without either medicine.
The trial tested two doses of admilparant, both taken twice a day. The lower dose slowed the loss of lung function over one year compared with placebo, meeting the trial’s main goal. The higher dose also showed some benefit, but the results were not strong enough to be certain that the medicine made a difference.
This is only the second time in a decade that an IPF clinical trial of this type has succeeded.
Why does this matter?
People living with IPF need more treatments that work well and are manageable to take. Existing medicines can slow the disease, but side effects can make it difficult for some people to continue treatment.
Encouragingly, the trial showed that few participants were unable to continue taking the treatment because of side effects, with similar rates of problems reported in the placebo group. This is particularly important given the challenges people face with existing treatments. Our State of the Nation report, published earlier this year, showed that 75% of people on current antifibrotics experienced multiple side effects.
However, only headline findings from the trial have been announced so far. Full results are needed to understand the size of the benefit and the medicine’s side effects and what the findings could mean for people living with IPF.
Bradley Price, Director of Policy, Research and Involvement at APF, said:
“People living with pulmonary fibrosis desperately need more options, and these results offer the potential for a new treatment that slows the disease and is manageable to take.
“We now need to see the full findings, including what they tell us about symptoms and daily life. Our priority is making sure that progress in research leads to meaningful change for people affected by pulmonary fibrosis.”
What happens next?
Admilparant will still need to go through regulatory approval and NHS assessment and access processes before it could become routinely available. There is currently no confirmed timeline for this, but we are committed to working with all relevant organisations to ensure this medicine is considered as soon as possible.
A separate trial looking at other types of progressive pulmonary fibrosis (PPF) is expected to report initial results in early 2027.
APF will follow the findings closely and keep our community informed. We will continue to champion research and timely, equitable access to effective new treatments.
You can help move research forward by supporting APF, sharing this story or finding out how to get involved in research.